Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Peng, Yun Peng ^a,b   Zhu, Yi ^a,b   Zhang, Jing Jing ^a,b   Xu, Ze Kuan ^a,b   Qian, Zhu Yin ^a,b   Dai, Cun Cai ^a,b   Jiang, Kui Rong ^a,b   Wu, Jun Li ^a,b   Gao, Wen Tao ^a,b   Li, Qiang ^a,b   Du, Qing ^a,b   Miao, Yi ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b Jiangsu Province Academy of Clinical Medicine   (China)

Author keywords

Cytotoxic granules; Digestive malignancies; NK cells; Surface receptors

Indexed keywords

DNAX ACCESSORY MOLECULE 1; GRANZYME B; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOLOGY; IMMUNOSURVEILLANCE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PANCREAS CANCER; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR ESCAPE; TUMOR INVASION;

COLORECTAL NEOPLASMS; CYTOPLASMIC GRANULES; FEMALE; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTORS, CELL SURFACE; STOMACH NEOPLASMS;

EID: 84885514189     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-262     Document Type: Article

References (39)

1. Zavoral M, Minarikova P, Zavada F, Salek C, Minarik M. Molecular biology of pancreatic cancer. World J Gastroenterol 2011, 17:2897-2908. 10.3748/wjg.v17.i24.2897, 3129504, 21734801.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29. 10.3322/caac.20138, 22237781.
3. Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006, 20:197-209. 10.1016/j.bpg.2005.10.001, 16549324.
4. Konjevic G, Jurisic V, Jovic V, Vuletic A, Martinovic MK, Radenkovic S, Spuzic I. Investigation of NK cell function and their modulation in different malignancies. Immunol Res 2012, 52:139-156. 10.1007/s12026-012-8285-7, 22442005.
5. Fogler WE, Volker K, McCormick KL, Watanabe M, Ortaldo JR, Wiltrout RH. NK cell infiltration into lung, liver, and subcutaneous B16 melanoma is mediated by VCAM-1/VLA-4 interaction. J Immunol 1996, 156:4707-4714.
6. Walzer T, Jaeger S, Chaix J, Vivier E. Natural killer cells: from CD3(-)NKp46(+) to post-genomics meta-analyses. Curr Opin Immunol 2007, 19:365-372. 10.1016/j.coi.2007.04.004, 17442558.
7. Bensussan A, Remtoula N, Sivori S, Bagot M, Moretta A, Marie-Cardine A. Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sezary syndrome patients. J Invest Dermatol 2011, 131:969-976. 10.1038/jid.2010.404, 21191411.
8. Correia DV, Fogli M, Hudspeth K, da Silva MG, Mavilio D, Silva-Santos B. Differentiation of human peripheral blood Vdelta1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 2011, 118:992-1001. 10.1182/blood-2011-02-339135, 21633088.
9. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001, 19:197-223. 10.1146/annurev.immunol.19.1.197, 11244035.
10. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285:727-729. 10.1126/science.285.5428.727, 10426993.
11. Bryceson YT, Ljunggren HG. Tumor cell recognition by the NK cell activating receptor NKG2D. Eur J Immunol 2008, 38:2957-2961. 10.1002/eji.200838833, 18979516.
12. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331:44-49. 10.1126/science.1198687, 3089969, 21212348.
13. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, Cantoni C, Grassi J, Marcenaro S, Reymond N, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003, 198:557-567. 10.1084/jem.20030788, 2194180, 12913096.
14. Parham P, Norman PJ, Abi-Rached L, Guethlein LA. Variable NK cell receptors exemplified by human KIR3DL1/S1. J Immunol 2011, 187:11-19. 10.4049/jimmunol.0902332, 3223120, 21690332.
15. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, Henter JI, Bennett M, Fischer A, de Saint Basile G, Kumar V. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999, 286:1957-1959. 10.1126/science.286.5446.1957, 10583959.
16. Chowdhury D, Lieberman J. Death by a thousand cuts: granzyme pathways of programmed cell death. Annu Rev Immunol 2008, 26:389-420. 10.1146/annurev.immunol.26.021607.090404, 2790083, 18304003.
17. Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells-enhancement by therapeutic antibodies. PLoS One 2007, 2:e326. 10.1371/journal.pone.0000326, 1828617, 17389917.
18. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev 2006, 20:123-137. 10.1016/j.blre.2005.10.001, 16364519.
19. McGilvray RW, Eagle RA, Watson NF, Al-Attar A, Ball G, Jafferji I, Trowsdale J, Durrant LG. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res 2009, 15:6993-7002. 10.1158/1078-0432.CCR-09-0991, 2778653, 19861434.
20. Hilpert J, Grosse-Hovest L, Grunebach F, Buechele C, Nuebling T, Raum T, Steinle A, Salih HR. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol 2012, 189:1360-1371. 10.4049/jimmunol.1200796, 22730533.
21. Garcia-Iglesias T, Del Toro-Arreola A, Albarran-Somoza B, Del Toro-Arreola S, Sanchez-Hernandez PE, Ramirez-Duenas MG, Balderas-Pena LM, Bravo-Cuellar A, Ortiz-Lazareno PC, Daneri-Navarro A. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer 2009, 9:186. 10.1186/1471-2407-9-186, 2704222, 19531227.
22. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, Goncalves A, Andre P, Romagne F, Thibault G, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011, 121:3609-3622. 10.1172/JCI45816, 3171102, 21841316.
23. Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A, Balsamo M, Conte R, Benelli R, Minghelli S, et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 2012, 72:1407-1415. 10.1158/0008-5472.CAN-11-2544, 22258454.
24. Koch J, Steinle A, Watzl C, Mandelboim O. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol 2013, 34:182-191. 10.1016/j.it.2013.01.003, 23414611.
25. Hecht ML, Rosental B, Horlacher T, Hershkovitz O, De Paz JL, Noti C, Schauer S, Porgador A, Seeberger PH. Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences. J Proteome Res 2009, 8:712-720. 10.1021/pr800747c, 19196184.
26. Kaifu T, Escaliere B, Gastinel LN, Vivier E, Baratin M. B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cell Mol Life Sci 2011, 68:3531-3539. 10.1007/s00018-011-0802-7, 21877119.
27. von Strandmann PE, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, Rothe A, Boll B, Simhadri VL, Borchmann P, et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007, 27:965-974. 10.1016/j.immuni.2007.10.010, 18055229.
28. Gur C, Enk J, Kassem SA, Suissa Y, Magenheim J, Stolovich-Rain M, Nir T, Achdout H, Glaser B, Shapiro J, et al. Recognition and killing of human and murine pancreatic beta cells by the NK receptor NKp46. J Immunol 2011, 187:3096-3103. 10.4049/jimmunol.1101269, 21849674.
29. Hudspeth K, Silva-Santos B, Mavilio D. Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. Front Immunol 2013, 4:69. 3603285, 23518691.
30. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436:1186-1190. 10.1038/nature03884, 1352168, 15995699.
31. Castriconi R, Cantoni C, Della CM, Vitale M, Marcenaro E, Conte R, Biassoni R, Bottino C, Moretta L, Moretta A. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 2003, 100:4120-4125. 10.1073/pnas.0730640100, 153058, 12646700.
32. Della Chiesa M, Carlomagno S, Frumento G, Balsamo M, Cantoni C, Conte R, Moretta L, Moretta A, Vitale M. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 2006, 108:4118-4125. 10.1182/blood-2006-03-006700, 16902152.
33. Saito H, Osaki T, Ikeguchi M. Decreased NKG2D expression on NK cells correlates with impaired NK cell function in patients with gastric cancer. Gastric Cancer 2012, 15:27-33.
34. Duan X, Deng L, Chen X, Lu Y, Zhang Q, Zhang K, Hu Y, Zeng J, Sun W. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med Oncol 2011, 28:466-474. 10.1007/s12032-010-9480-9, 20354827.
35. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM, Raulet DH. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008, 28:571-580. 10.1016/j.immuni.2008.02.016, 3528789, 18394936.
36. Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002, 169:4098-4102.
37. Smyth MJ, Swann J, Kelly JM, Cretney E, Yokoyama WM, Diefenbach A, Sayers TJ, Hayakawa Y. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J Exp Med 2004, 200:1325-1335. 10.1084/jem.20041522, 2211920, 15545356.
38. Peruzzi M, Parker KC, Long EO, Malnati MS. Peptide sequence requirements for the recognition of HLA-B*2705 by specific natural killer cells. J Immunol 1996, 157:3350-3356.
39. Al Omar S, Middleton D, Marshall E, Porter D, Xinarianos G, Raji O, Field JK, Christmas SE. Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. Hum Immunol 2010, 71:976-981. 10.1016/j.humimm.2010.06.019, 20600442.